Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel

Bevacizumab plus weekly paclitaxel improves progression-free survival (PFS) in HER2-negative metastatic breast cancer (mBC), but its use has been questioned due to the absence of a predictive biomarker, lack of benefit in overall survival (OS) and increased toxicity. We examined the baseline tumor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendiola, Marta, Martínez-Marin, Virginia, Herranz, Jesús, Heredia, Victoria, Yébenes, Laura, Zamora, Pilar, Castelo, Beatriz, Pinto, Álvaro, Miguel, María, Díaz, Esther, Gámez, Angelo, Fresno, Juan Ángel, de Molina, Ana Ramírez, Hardisson, David, Espinosa, Enrique, Redondo, Andrés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029696/
https://www.ncbi.nlm.nih.gov/pubmed/26992213
http://dx.doi.org/10.18632/oncotarget.8128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029696/
https://www.ncbi.nlm.nih.gov/pubmed/26992213
http://dx.doi.org/10.18632/oncotarget.8128

Ejemplares similares